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Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of
lymphomas has rapidly evolved overtime with significant improvement in the cure rate
and reductions in treatment-related toxicities. Despite excellent results, treatment pro-
grams are continued to be developed to achieve better curative and safety profiles. In
these patients individualized therapy schemes can be devised based on a well-defined
risk categorization. The therapy efficacy can be increased early during therapy in non-
responding patients with escalated therapy protocols or with the addition of radiation
therapy, particularly, in advanced-stage or unfavorable risk patients.The increasing availabil-
ity of positron emission tomography using 18F-fluorodeoxyglucose, particularly fused with
computed tomography (FDG-PET/CT) has lead to the integration of this modality into the
routine staging and restaging for lymphoma with convincing evidence that it is a more accu-
rate imaging modality compared with conventional imaging techniques. FDG-PET/CT is also
is a promising surrogate for tumor chemosensitivity early during therapy. This review will
summarize published data on the utility of FDG-PET/CT imaging in the staging, restaging,
and predicting therapy response in patients with lymphoma.
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INTRODUCTION
The lymphomas are a heterogeneous group of diseases with
respect to their biology, treatment, and prognosis. Despite the
high rate of cure of Hodgkin lymphoma (HL) and diffuse large
B-cell lymphoma (DLBCL), there is a need to alter therapy in
patients unlikely to benefit from standard treatment, while reduc-
ing treatment intensity in patients with low risk disease. To
achieve this goal requires not only an accurate staging system,
but strong baseline risk factors (prognostic), and/or those early
during therapy (predictive factors) to define the optimal treat-
ment strategy. Positron emission tomography (PET) using F-18-
fluorodeoxyglucose (FDG), integrated with computed tomogra-
phy (CT) (PET/CT) has become widely used in the staging and
evaluation of therapy response in lymphomas, and may provide
the means for such an individualized approach.
HISTOPATHOLOGIC LYMPHOMA SUBTYPES
F-18-fluorodeoxyglucose-avidity varies among the various lym-
phoma subtypes, the most routinely avid being HL, DLBCL,
Burkitt, mantle cell (MCL), follicular lymphoma (FL) with a
PET/CT sensitivity of 85–100% (1–6). There is currently no estab-
lished role for the clinical usefulness of FDG-PET/CT in the less
common indolent NHLs including marginal zone lymphomas
(MZL), chronic lymphocytic leukemia/small lymphocytic lym-
phoma (CLL/SLL), and lymphoplasmacytic lymphoma (LPL),
that tend to have limited and variable FDG-avidity (3, 7–12).
About 10% of NHLs are of T-cell origin (13) and FDG-PET avidity
is variable; being most reliable for the more aggressive, nodal
subtypes including peripheral T-cell lymphoma not otherwise
specified and anaplastic large cell lymphoma (12, 13).
F-18-fluorodeoxyglucose-avidity appears to correlate with
aggressiveness of lymphomas (14, 15) and imaging with FDG-
PET may be helpful in identifying a potential site of histologic
transformation. It is important to note that SUVs exceeding 10
yields 80% certainty for the identification of aggressive behavior
(16, 17), particularly, in Richter’s transformation for patients with
CLL/SLL (18).
STAGING OF LYMPHOMAS
Ann Arbor staging, the most widely used system, has evolved
over the past 40 years to incorporate CT (19, 20). Nevertheless,
anatomic imaging relies on size and location and, therefore, is
unable to distinguish malignant from benign lymph nodes (21).
Numerous studies and a meta-analysis demonstrate that FDG-PET
is more accurate than CT at initial staging with a maximum joint
sensitivity and specificity of 96% on a lesion basis (22), which far
exceeded the corresponding values for contrast-enhanced com-
puted tomography (CECT) (2, 9, 22–26). Discordance between
PET and CECT findings occurs in approximately one third of
patients at initial staging,predominantly, in favor of PET/CT imag-
ing (22, 24, 26–32); however, stage is uncommonly altered (in up
to 30% of patients), and treatment is rarely changed (in up to 15%
of patients) with no evidence that outcome is improved as a result
of these data (2, 24–29, 36–42). It is important to realize that the
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widespread use of systemic chemotherapy in lymphoma patients
appears to mitigate the need for a precise determination of the
anatomic extent of disease; however, staging PET/CT is integral to
evaluation of subsequent response to therapy.
The International Harmonization Project (IHP) recommends
a baseline FDG-PET scan for HL and DLBCL because of their
consistent FDG-avidity and potential curability (33). For other
subtypes, FDG-PET imaging is recommended for clinical tri-
als, particularly, when response rate is the primary objective.
The current National Comprehensive Cancer Network guidelines
(NCCN) recommend baseline PET imaging as an essential test in
HL, DLBCL, AIDS related B-cell lymphomas and as a useful test
in selected cases in FL, MZL, MCL, but does not recommend it in
CLL/SLL (34, 35).
PET PLUS CECT AT STAGING
Whether the addition of a CECT improves the sensitivity and
specificity of PET/CT remains controversial (24, 25, 32, 41–46). In
a series of 103 NHL and HL patients, Raanani et al. reported that
the addition of CECT to PET/CT changed management in only
about 10% of patients while FDG/PET resulted in a management
change in almost 50% of HL patients compared with CECT alone
(41). However this study described neither what type of treatment
changes occurred nor whether outcome was altered. In a group of
47 NHL or HL patients, Rodríguez-Vigil et al. reported no signifi-
cant differences between the use of unenhanced low-dose PET/CT
and contrast-enhanced full-dose PET/CT, although PET/CECT
produced fewer indeterminate findings and identified a higher
number of extranodal sites (42). These results suggest a marginal
benefit with the addition of CECT to PET examination. In cur-
rent practice, management of lymphoma usually requires both
CECT and low-dose FDG-PET/CT for morphologic and meta-
bolic assessment, respectively. However, this strategy increases
patient radiation exposure by up to twofold (45).
Contrast-enhanced computed tomography is advisable in
patients with abdominal lymphomas for distinguishing lymph
nodes from non-opacified bowel loops and vessels, and where
more precise measuring of node size is indicated. In rare cases
with head and neck involvement, CECT may be useful to differ-
entiate physiologic uptake from enlarged cervical lymph nodes.
While in lymphomas with variable and low-grade FDG uptake
including CLL/SLL and MZL, and some PTCL (3, 8, 14, 47, 48),
CECT should be the imaging modality of choice. Further consid-
eration for the use of both FDG-PET and CECT includes patients
who are planned to undergo radiation therapy.
FDG-PET IN BONE MARROW INVOLVEMENT
Accurate assessment of the BM is crucial because it often upstages
disease, leading to alterations in therapy strategy (5, 6). Lymphoma
involvement of the BM is more common in patients with NHL
(20–30%) (49, 50), especially, in indolent subtypes and MCL com-
pared to those with HL (10%). BM biopsy is known to have a
substantial false-negative rate due to the small volume of samples
(51), and that it does not evaluate marrow involvement outside
the pelvis. The sensitivity of PET in detecting BM involvement
in HL and NHL, primarily in DLBCL, is about 90 and 75%,
respectively (52–59) while only a sensitivity of 50% was achieved
in indolent NHL (52, 53). The lower sensitivity seen in DLBCL
can be explained by discordant lymphoid infiltrates representing
the low-grade component of disease that lowers the sensitivity of
FDG-PET imaging (49, 50). Although BMB remains essential for
the diagnostic work-up only rarely do the early stage HL patients
have BM involvement (58–60). BMB should no longer be recom-
mended for staging clinically advanced HL because the marrow
is virtually never involved in the absence of constitutional symp-
toms or other evidence of stage IV disease (60). Consequently,
routine BMB should be restricted to patients with NHL. Patients
with DLBCL rarely have a positive bone marrow biopsy in the
absence of focal or diffuse involvement by PET-CT, or who have
other evidence of advanced disease and, therefore, this procedure
should be restricted to those with a positive scan to assess for the
presence of a discordant histology. Even in indicated patients FDG-
PET should precede BMB and biopsy or MRI could be pursued for
confirmation of a positive PET finding. In the post-therapy setting,
one should be mindful of the reactive BM changes induced by the
colony stimulating factors (i.e., G-CSF). A 4–6 week period of time
should be allowed before post-therapy PET imaging in patients
who have received G-CSF to minimize the risk of a false-positive
interpretation of the BM.
EVALUATION OF RESPONSE AFTER COMPLETION OF
THERAPY
Perhaps the clearest role for the use of PET in lymphoma is in
post-treatment response assessment because of its ability to dis-
tinguish fibrosis or sclerosis from residual active disease. Early
studies have demonstrated a role for post-therapy FDG-PET imag-
ing in the prediction of aggressive NHL or HL recurrence (61–69).
A negative (NPV) and a positive predictive value (PPV) of 80
and 100% were reported for FDG-PET in the identification of
residual aggressive NHL after completion of first-line chemother-
apy (66). In HL patients, studies demonstrate significantly shorter
progression-free survivals (PFS) for PET-positive patients (0–4%)
compared with 85–95% for those with a negative scan (62, 63, 68,
69). The revised International Working Group response criteria
(rIWG) incorporated FDG-PET to accurately assess post-therapy
persistent masses in both NHL and HL (33). The rIWG-PET inter-
pretation criteria (i.e., IHP criteria) eliminated the terminology of
“complete remission/unconfirmed (CRu)” on the basis of better
response characterization provided by FDG-PET imaging. How-
ever, there is a need to prospectively validate these criteria in HL
and DLBCL after first-line therapy as the majority of prior studies
using IHP were based on retrospective data.
INDOLENT LYMPHOMAS
Limited FDG-PET data exist for FDG-PET in low-grade NHL (7,
70–74). In 45 untreated FL patients, Le Dortz et al. reported a
median PFS of 48 and 17.2 months in the PET/CT-negative and
positive groups, respectively, after four or six cycles of induction
immunochemotherapy (7). Similar results were obtained by Bishu
et al. in a retrospective review of 31 FL patients treated mainly with
R-CHOP therapy (70). In another series of 39 relapsed or refrac-
tory FL patients, after completion of bendamustine therapy, the
percent reduction in SUVmax (70 vs. 29%) and in maximum per-
pendicular diameters (78 vs. 48%) were significantly greater in
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patients achieving a CR than in those with non-CR (71). The use
of PET at the end-of-treatment in high-tumor-burden FL is sup-
ported by the emerging data. The utility of FDG-PET/CT in assess-
ing response at the end of induction immunochemotherapy was
suggested by the Primary Rituximab and Maintenance (PRIMA)
study by the GELA in high-tumor-burden FL patients (72, 73).
Patients remaining PET-positive had a significantly inferior PFS
at 42 months than in those who became PET-negative (33 vs.
71%, p< 0.001) in a subgroup of 122 patients (73). Similarly in a
prospective study of 121 previously untreated high-tumor-burden
FL patients at the end-of-treatment (first-line immunochemother-
apy with six cycles of R-CHOP plus two cycles of rituximab, with-
out rituximab maintenance) (74). When the response was assessed
using Deauville criteria, with a median follow-up of 23 months,
2 year PFS was 87% for final PET-negative vs. 51% for final PET-
positive patients (p< 0.001), respectively. End-of-treatment, but
not interim scans, were predictive of 2 year OS for positive and
negative scans (p= 0.013).
STEM CELL TRANSPLANTATION
A current standard treatment for relapsed or refractory HL
involves high-dose chemotherapy and autologous hematopoietic
stem cell transplantation (HDT/ASCT), offering long-term dis-
ease free survival in more than 50% of transplanted patients (75).
Favorable outcome is largely a function of chemosensitivity at
the time of ASCT (76–84). In recent studies in HL, best ASCT
response was obtained in patients with chemosensitive disease
who were PET-negative (76–80) after salvage therapy regardless of
the chemotherapy that induced the response (79). A recent meta-
analysis from 12 studies with 630 patients (187 HL; 313 DLBCL)
reported a sensitivity of 69% and specificity of 81% (83). Addi-
tionally, PET-positive disease was associated with a significantly
inferior 3 year PFS or EFS (31–41%) compared with patients who
had PET-negative results following salvage chemotherapy prior to
ASCT (75–82%) (76–78). Similar results were obtained in a ret-
rospective case-series of 39 primary refractory or relapsed DLBCL
patients with 3 year PFS of 35 vs. 81% for patients with positive
pre-ASCT PET vs. those who had a negative PET (p= 0.003) (85).
Consequently, post-salvage therapy FDG is recommended to dif-
ferentiate patients with a better prognosis following ASCT from
others with unfavorable prognosis.
RESPONSE EVALUATION DURING THERAPY
Rapid response to chemotherapy is a recognized surrogate marker
of chemosensitivity in both HL and DLBCL with an attendant
high likelihood of a longer PFS (86). Persistent FDG uptake after
two to four cycles of chemotherapy is associated with relapse
rates ranging from 50 to 100%, while the relapse rate in interim-
PET-negative patients is usually lower than 10% (87–92). In a
meta-analysis, interim FDG-PET yielded an overall sensitivity of
81% and a specificity of 97% for advanced-stage HL, and a sensitiv-
ity of 78% and a specificity of 87% for DLBCL (93). Nonetheless,
more recently, the results obtained for DLBCL patients were less
convincing (94).
In advanced-stage HL patients (n= 260), after two cycles
(PET2) of standard therapy, Gallamini et al. reported treatment
failure in 86% of PET2-positive patients after a median follow-up
of 2.2 years while 95% of PET2-negative patients remained in CR
(88). Interim-PET results have also been shown to be a stronger
predictive factor for PFS than the International Prognostic Score
(IPS) (88, 91). Similarly, in another non-randomized prospective
study of mixed stage HL patients, Cerci et al. reported a 3-year EFS
of 55 and 94% for PET2-positive and negative patients, respec-
tively (p< 0.001) (95). However, these data should also be inter-
preted with caution because IPS categories were not restricted to
advanced-stage patients and unfavorable factors were disregarded
in the stage classification.
The role of FDG-PET in the prediction of ultimate outcome is
clearer in advanced-stage than early stage HL (93–103). Hutchings
et al. reported a PPV of only 30% for an interim-PET after two
or three cycles of ABVD chemotherapy in early stage HL (90, 91)
while the NPV was high at 95%. More recently, in limited stage
non-bulky HL patients the enthusiasm for interim-PET imaging
has been tempered with no clear difference noted between PET2-
positive and negative patients with respect to PFS (87 vs. 91%;
p= 0.57) (98). By contrast, end-chemotherapy PET was highly
predictive of PFS (94 vs. 54%; p< 0.0001). However, these are
retrospective data with no control imposed over PET acquisition
protocols and standardization of timing which are essential factors
to provide reliability and reproducibility for the results.
Another important consideration is that the effectiveness of
therapy has an influence on the predictive value of any given
predictive marker. Using a slightly less effective chemotherapy
regimen (doxorubicin, vinblastine, and gemcitabine), in a non-
randomized prospective study of early non-bulky HL, Straus et al.
reported a lower than expected 2 year PFS at 88% for PET2 neg-
ative patients while the PFS was 54% in the PET2-positive group
(p= 0.0009), (96, 97). Similarly, in a randomized, prospective trial
by Le Roux et al. early and advanced-stage HL patients were treated
with a therapeutic strategy adapted to baseline prognostic factors,
interim-PET after four cycles of ABVD (PET4) and CECT (99).
The negative NPV and PPV for the interim FDG-PET predict-
ing 2 year PFS were 96 and 16%, respectively (p< 0.0001). The
inferior PPV obtained in this study is not surprising as treatment
intensification schemes may negate the predictive value of PET
positivity.
Based on compelling data on interim-PET in advanced-stage
HL, multiple PET-directed randomized studies were initiated to
determine the outcome of therapy escalation in non-responding
patients as well as de-escalation in patients who achieve an early
CR. But, only few have reported interim results (100–104). In the
HD15 trial of the German Hodgkin Study Group (GHSG), HL
patients (stages IIB, III, IV) were initially randomized to one of
three induction regimens (102). Those with a residual mass of
at least 2.5 cm underwent a PET scan. Patients with a negative
study were not further treated, whereas those with a positive scan
received involved field radiation. The frequency of consolidative
IFRT was only 11% compared with 70% in prior studies antedat-
ing the use of PET scans, with no difference in overall survival.
In a retrospective analysis of a prospective study by Gallamini et
al. in advanced-stage HL (GITIL/HD0607) when the treatment of
PET2-positive patients was escalated to BEACOPP (bleomycin,
etoposide, adriamycin, cyclophosphamide, vincristine, procar-
bazine, and prednisone) regimen the FFS was 95% in PET2
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negative and 62% in PET2-positive groups (p< 0.0001) with a
median follow-up of 34 months which was superior to the 15%
in patients whose therapy was unchanged (103). Another adap-
tive therapy trial in advanced-stage HL by Dann et al. using not
only interim-PET results but also the IPS for stratifying patients
into different therapy arms reported a 10-year PFS of 83% in
interim-PET-positive patients compared with 93% for those with
a negative interim-PET (ns) suggesting that unfavorable outcomes
can be overcome by therapy intensification (100).
In the RAPID trial, patients with limited stage disease received
three cycles of ABVD (104). Those who were PET-positive received
an additional cycle followed by radiation therapy. The negative
patients were randomized to involved field RT or observation, the
latter being shown to be non-inferior. These results support the
use of PET in risk-adapted strategies.
In DLBCL, while FDG-PET at completion of therapy is a good
predictor of outcome, the value of an interim-PET remains con-
troversial because of its low PPV (93). Although earlier studies
supported a role for an interim FDG-PET performed after two
to four cycles of standard chemotherapy, the results of these and
later studies varied significantly among patient groups (105–107).
The 2-year PFS for the PET-negative groups was 82–93% in PET-
negative while the PFS for the PET-positive groups varied from 0
to 43%. These differences in PET results may be related to vary-
ing follow-up periods, patient populations, and different types
of treatments employed, i.e., standard chemotherapy alone or
with immunotherapy (rituximab). To further clarify the clini-
cal relevance of interim FDG-PET, in a risk-adapted dose-dense
immunochemotherapy program, Moskowitz et al. reported simi-
lar PFS for interim-PET-positive/biopsy-negative patients and in
interim-PET-negative patients during a follow-up of 44 months
(94). In PET-positive patients, repeat biopsy was negative in
87%, and 51% of these patients remained progression-free after
consolidation therapy during follow-up.
To date, the majority of interim FDG-PET studies have used
visual criteria. However, the results of the GELA trial (LNH2007-
3B) of 85 high-risk DLBCL patients suggested that those patients
whose tumors had a percent SUV change (∆SUVmax) of >66%
between baseline and after two cycles of therapy (2 year PFS 77 vs.
57%; p= 0.028) and>70% between baseline and after four cycles
(2 year PFS 83 vs. 40%; p< 0.0001) could be spared high-dose
therapy (108). On the contrary, outcomes did not differ signifi-
cantly whether PET2 and PET4 were visually positive or negative.
The GAINED trial by the same investigators is designed to further
demonstrate the superiority of quantitative approach over visual
interpretation (109).
In summary, in advanced-stage HL, encouraging data exist
on the effectiveness of interim FDG-PET/CT as a surrogate for
chemosensitivity. However, there is limited evidence that chang-
ing treatment based solely on interim-PET-CT results improves
patient outcome. Interim-PET-adapted therapy strategies should
be pursued only in a clinical trial setting until the value of interim-
PET is proven by ongoing prospective,“response-adapted”therapy
trials. The role of FDG-PET in DLBCL and early stage HL are not
supported by the available data. Furthermore, there is no evidence
to suggest that an early therapy change in the poorly responding
patients will translate into a survival benefit.
SURVEILLANCE FOLLOWING FIRST-LINE THERAPY
Despite improvements in survival rates, relapses occur in approxi-
mately 30–50% of advanced-stage HL and DLBCL patients follow-
ing first-line therapy (110–112). In a meta-analysis, the sensitivity
and specificity of FDG-PET in identifying disease relapse for HL
were 50–100 and 67–100%, respectively, and for NHL 33–77 and
82–100%, respectively, irrespective of a residual mass on CT (113).
In a recent study of HL and aggressive NHL, more than 60% of
relapses were diagnosed clinically, especially, in aggressive NHL
and in cases with extranodal involvement. Although HL relapses
were more commonly detected by FDG-PET scans because of
clinically silent disease, no survival benefit was proven (114).
In another study of 421 patients with mixed histologies includ-
ing HL, aggressive NHL, and FL after first complete remission,
serial six monthly FDG-PET scans enabled detection of relapse
within 18 months of therapy (115). There are also conflicting
results reporting a PPV of only 30% for FDG-PET in HL patients
(116).
In summary, survival does not appear to be affected by mode
of detection of recurrent lymphoma or the frequency of imaging.
The low PPV associated with follow-up FDG-PET scans negates
their clinical value in identifying patients who would benefit from
additional treatment (117, 118).
GENERAL CONSIDERATIONS AND RECOMMENDATIONS
TIMING OF FDG-PET IMAGING
• Interim-PET should be scheduled within 4–5 days of start of the
subsequent therapy cycle to minimize false-positive results pro-
duced by the florid inflammatory response that peaks at around
day 10 of chemotherapy initiation (118, 119).
• The timing of FDG-PET studies after chemotherapy comple-
tion is more flexible, a 6- to 8-week window after end of therapy
should be observed to allow for inflammation to subside and
to minimize false-positive results caused by the inflammatory
response associated with rituximab therapy (120).
• Although, the bulk of existing data supports the use of interim-
PET after two cycles of treatment in HL, there is no established
optimal timing with regards to therapy cycles. If and when a par-
adigm shift toward tailored approach is established, performing
PET after two cycles seems reasonable. There is also evidence
that PET after one cycle has a high negative predictive value
with respect to PFS (121, 122).
STANDARDIZATION OF FDG-PET INTERPRETATION
• The International Harmonization Project criteria were devel-
oped for evaluation of response after completion of therapy.
IHP criteria use the mediastinal blood pool as an internal ref-
erence for lesions of 2.0 cm or larger to discriminate a positive
finding from a negative (118).
• To increase the specificity of PET readings, the definition of a
positive interim-PET result has evolved from any uptake above
background to uptake intensity that is equal to the mediasti-
nal blood pool, i.e., IHP criteria (118), and more recently to an
intensity exceeding the background in the liver (122, 123).
• For interim-PET readings, a relatively high cut off is appropri-
ate to measure chemosensitivity. Recently proposed “Deauville
criteria” yield a flexible reading scheme suitable for different
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positivity thresholds to adjust for the intended treatment
end-points (122, 123).
• Deauville criteria have recently been validated in a retrospec-
tive cohort of 260 advanced-stage HL patients treated with
ABVD (124). After a mean follow-up of 27.2 months, the 3-
year PFS of PET2-positive and negative patients were 28 and
95%, respectively (p< 0.001). The binary concordance between
paired reviewers was high (k Cohen: 0.84).
• The widely recognized challenge to the integration of interim-
PET into management schemes is the variability and the high
false-positive rates associated with visual evaluation, particularly
in those with bulky residual masses.
SEMI-QUANTITATIVE EVALUATION
• Metabolic changes determined by the SUV which is adjusted
for body weight and administered activity, provide a continuous
and objective scheme of measurements that are more compatible
with the kinetics of in vivo therapy response.
• The change in tumor SUVmax before and after treatment can
be used as a measure of response. However, strict adherence to
protocols for all imaging periods are necessary because SUV
measurements depend on multiple variables including time
interval after injection, blood glucose level, body weight, and
technical PET parameters.
• The use of quantitation to improve upon visual assessment was
explored in DLBCL after two and four cycles of chemotherapy
by Casasnovas et al. (108, 125). The results of this study have
been previously discussed in Section“Early Response Evaluation
during Therapy.”
• Further studies are needed to define a widely accepted semi-
quantitative approach for lymphoma, probably with slightly
different values for each subtype.
FUTURE DIRECTIONS IN QUANTITATIVE PET ASSESSMENTS
• Disease bulk at initial presentation has long been a known
adverse prognostic factor, particularly in early stage HL (126).
Several methods can be used to measure disease bulk, includ-
ing the mediastinal-thoracic ratio and maximum size of the
largest mass. However, studies are underway to evaluate PET-
based metabolic tumor volume (MTV) or total lesion glycolysis
(TLG) as more accurate methods to determine disease bur-
den by accounting for the whole body tumor volume using
sophisticated software systems (127–130).
• Preliminary MTV data are available for patients with DLBCL
(131, 132). In 169 stage II-III DLBCL patients treated with R-
CHOP, multivariate analysis revealed an association between
high MTV group and lower PFS and OS during a median follow-
up of 36 months (p< 0.001), but not with stage III (p= 0.054)
(131). These results suggest a higher predictive power for MTV
compared to Ann Arbor staging in DLBCL patients.
• The prognostic value of these automated volumetric meth-
ods will be determined after the establishment of the opti-
mal method for determining the most accurate tumor
volume.
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